Zhaoke Ophthalmology-B: Beimei Prostaglandin Eye Drops (Jingbeiqing®) Approved by the National Medical Products Administration for Marketing
Zhaoke Ophthalmology-B announced that its research and development of the anti-glaucoma drug Bimatoprost eye drops (Crystal Clear®) has been approved by the National Medical Products Administration for marketing. This is the first single-dose Bimatoprost eye drops in China without preservatives, aimed at reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension, improving patient comfort, and enhancing medication compliance
According to the Zhitong Finance and Economics APP, MegaMed Eye Care-B (06622) announced that their self-developed and produced anti-glaucoma drug, Bemiprost Eye Drops (Jingbeiqing®), has been approved for listing by the National Medical Products Administration (NMPA).
Bemiprost Eye Drops (Jingbeiqing®) is the first preservative-free single-dose Bemiprost eye drops in China, used to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension. This medication does not contain preservatives, avoiding damage to the ocular surface caused by long-term use of preservative-containing drugs in glaucoma patients. At the same time, this medication also helps improve patient comfort during treatment, reducing the risk of preservative-related sensitivity. Its once-daily dosing frequency also helps improve patient compliance